Oculis (NASDAQ:OCS) Trading Up 4.5% – What’s Next?

Oculis Holding AG (NASDAQ:OCS) traded up 4.5% during trading on Tuesday . The company traded as high as $15.50 and last traded at $15.45. 2,641 shares traded hands during mid-day trading, a decline of 93% from the average session volume of 36,890 shares. The stock had previously closed at $14.79.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and issued a $30.00 target price on shares of Oculis in a research report on Monday, November 11th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $29.20.

Oculis Stock Up 5.1 %

The company has a market capitalization of $654.48 million, a P/E ratio of -7.96 and a beta of -0.16. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.02 and a current ratio of 4.02. The firm’s fifty day moving average is $14.71 and its 200-day moving average is $12.82.

Oculis (NASDAQ:OCS) last announced its quarterly earnings results on Tuesday, August 27th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.13). Oculis had a negative return on equity of 71.31% and a negative net margin of 8,043.28%. The company had revenue of $0.27 million for the quarter, compared to analyst estimates of $0.28 million. As a group, equities research analysts predict that Oculis Holding AG will post -2.09 EPS for the current year.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.